Professor, School of Medicine, University of California, Davis

Neurology

Dr. Michael A. Rogawski practices Neurology. He attended Yale University School of Medicine. Yale University School of Medicine is a one of the best medicals schools. Yale University School of Medicine has a rank of 7 in research and a 57 in primary care He received 1 awards: "CMS Meaningful Use Stage 1 Certification". Michael A. Rogawski, MD is also published. He has 101 publications published. The lastest publication: "Hirschsprung''s disease: absence of serotonergic neurons in the aganglionic colon.' Michael A. Rogawski accepts all Medicare patients.

Publications

---

• Is a separate monotherapy indication warranted for antiepileptic drugs?
• Evaluation of the neuroactive steroid ganaxolone on social and repetitive behaviors in the BTBR mouse model of autism.
• Contrasting actions of a convulsant barbiturate and its anticonvulsant enantiomer on the α1 β3 γ2L GABAA receptor account for their in vivo effects.
• Post-exposure administration of diazepam combined with soluble epoxide hydrolase inhibition stops seizures and modulates neuroinflammation in a murine model of acute T...
• The Riluzole Derivative 2-Amino-6-trifluoromethylthio-benzothiazole (SKA-19), a Mixed KCa2 Activator and Na V Blocker, is a Potent Novel Anticonvulsant.
• Role of GluK1 Kainate Receptors in Seizures, Epileptic Discharges, and Epileptogenesis.
• Anticonvulsant potencies of the enantiomers of the neurosteroids androsterone and etiocholanolone exceed those of the natural forms.
• Seizure protection by intrapulmonary delivery of midazolam in mice.
• Long-lasting attenuation of amygdala-kindled seizures after convection-enhanced delivery of botulinum neurotoxins a and B into the amygdala in rats.
• Neuroactive steroids for the treatment of status epilepticus.
• Issues related to development of new antiseizure treatments.
• Proconvulsant actions of intrahippocampal botulinum neurotoxin B in the rat.
• The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs.
• AMPA receptors as a molecular target in Epilepsy therapy.
• Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist.
• How theories evolved concerning the mechanism of action of barbiturates.
• Altered fast and slow inactivation of the N440K Nav1.4 mutant in a periodic paralysis syndrome.
• Tetramethylenedisulfotetramine Alters Ca2+ Dynamics in Cultured Hippocampal Neurons: Mitigation by NMDA Blockade and GABAA Receptor Positive Modulation.
• Adjunctive perampanel for refractory partial-onset seizures: Randomized phase III study 304.
• Clustered burst firing in FMR1 premutation hippocampal neurons: amelioration with allopregnanolone.
• Compromised Function in the Na(v)1.2 Dravet Syndrome Mutation R1312T.
• Propofol hemisuccinate suppresses cortical spreading depression.
• Role of Neurosteroids in the Anticonvulsant Activity of Midazolam.
• Disclosure of clinical trial results when product development is abandoned.
• Treatment of Infantile Spasms: Emerging Insights From Clinical and Basic Science Perspectives.
• 11β-Hydroxylase inhibitors protect against seizures in mice by increasing endogenous neurosteroid synthesis.
• Revisiting AMPA receptors as an antiepileptic drug target.
• Seizure protection by intrapulmonary delivery of propofol hemisuccinate.
• A new policy for Disclosure of competing interests.
• To Our Readers and the AES Membership.
• Neurosteroids on the Epilepsy chessboard-keeping seizures in check.
• Anticonvulsant and proconvulsant actions of 2-deoxy-D-glucose.
• Treatment of early and late kainic acid-induced status epilepticus with the noncompetitive AMPA receptor antagonist GYKI 52466.
• Topiramate reduces excitability in the basolateral amygdala by selectively inhibiting GluK1 (GluR5) kainate receptors on interneurons and positively modulating GABAA r...
• Neurosteroid replacement therapy for catamenial Epilepsy.
• Convection-enhanced delivery in the treatment of Epilepsy.
• Nontraditional Epilepsy treatment approaches.
• Neurosteroids and epileptogenesis in the pilocarpine model: evidence for a relationship between P450scc induction and length of the latent period.
• Intrinsic severity as a determinant of antiepileptic drug refractoriness.
• New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels.
• Common pathophysiologic mechanisms in migraine and Epilepsy.
• The anticonvulsant activity of acetone does not depend upon its metabolites.
• Efficacy of the ketogenic diet in the 6-Hz seizure test.
• Prolonged attenuation of amygdala-kindled seizure measures in rats by convection-enhanced delivery of the N-type calcium channel antagonists omega-conotoxin GVIA and o...
• Calcium currents burst Back: a possible role for dendrites in epileptogenesis.
• The neuropharmacology of the ketogenic diet.
• The anticonvulsant activity of acetone, the major ketone body in the ketogenic diet, is not dependent on its metabolites acetol, 1,2-propanediol, methylglyoxal, or pyr...
• The ketogenic diet: stoking the powerhouse of the cell.
• Molecular targets for antiepileptic drug development.
• Point-counterpoint: Do interictal spikes trigger seizures or protect against them?
• Endogenous neurosteroids modulate epileptogenesis in a model of temporal lobe Epilepsy.
• Support for the NIH public access policy.
• The pheromone androstenol (5 alpha-androst-16-en-3 alpha-ol) is a neurosteroid positive modulator of GABAA receptors.
• Update on the neurobiology of alcohol withdrawal seizures.
• Astrocytes get in the act in Epilepsy.
• Anticonvulsant activity of androsterone and etiocholanolone.
• Regulation of brain water: is there a role for aquaporins in Epilepsy?
• Adult murine skeletal muscle contains cells that can differentiate into beating cardiomyocytes in vitro.
• Cerebellar ataxia, seizures, premature death, and cardiac abnormalities in mice with targeted disruption of the Cacna2d2 gene.
• The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions.
• What is the rationale for new treatment strategies in Alzheimer's disease?
• Allopregnanolone analogs that positively modulate GABA receptors protect against partial seizures induced by 6-Hz electrical stimulation in mice.
• Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons.
• GluR5 kainate receptors, seizures, and the amygdala.
• Progesterone, neurosteroids, and the hormonal basis of catamenial Epilepsy.
• The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease.
• Does P-glycoprotein play a role in pharmacoresistance to antiepileptic drugs?
• Antiepileptogenesis by Deep Brain Stimulation.
• The Epileptic Neuron Redux.
• Epileptiform activity extinguished by amygdala infusion of the neurotoxin ibotenate in a rat model of temporal lobe Epilepsy.
• Stress-induced deoxycorticosterone-derived neurosteroids modulate GABA(A) receptor function and seizure susceptibility.
• New Evidence Supporting a Role for T-Type Ca(2+) Channels in Absence Epilepsy and in the Action of Ethosuximide.
• Neurosteroids and infantile spasms: the deoxycorticosterone hypothesis.
• Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania.
• Proceedings:Pre- and postsynaptic actions of neuroleptic drugs.
• Effect of selective destruction of central and peripheral catecholamine-containing neurones with 6-hydroxydopamine on catecholamine excretion in the rat.
• Diverse mechanisms of antiepileptic drugs in the development pipeline.
• Evidence for low GluR2 AMPA receptor subunit expression at synapses in the rat basolateral amygdala.
• Molecular targets versus models for new antiepileptic drug Discovery.
• Anxiolytic activity of progesterone in progesterone receptor knockout mice.
• Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist.
• The neurobiology of antiepileptic drugs.
• Effects of neurosteroids on epileptiform activity induced by picrotoxin and 4-aminopyridine in the rat hippocampal slice.
• New strategies for the identification of drugs to prevent the development or progression of Epilepsy.
• "Jasper's Basic Mechanisms of the Epilepsies" Workshop.
• Termination of epileptiform activity by cooling in rat hippocampal slice Epilepsy models.
• Neuroprotective and disease-modifying effects of the ketogenic diet.
• Ganaxolone suppression of behavioral and electrographic seizures in the mouse amygdala kindling model.
• 17beta-Nitro-5alpha-androstan-3alpha-ol and its 3beta-methyl derivative: neurosteroid analogs with potent anticonvulsant and anxiolytic activities.
• Brivaracetam: a rational drug Discovery success story.
• Pathological alterations in GABAergic interneurons and reduced tonic inhibition in the basolateral amygdala during epileptogenesis.
• Anticonvulsant activity of progesterone and neurosteroids in progesterone receptor knockout mice.
• Clinical spectrum of succinic semialdehyde dehydrogenase deficiency.
• Comparison of the effects of neuroleptic drugs on pre- and postsynaptic dopaminergic mechanisms in the rat striatum.
• Melatonin: deacetylation to 5-methoxytryptamine by liver but not brain aryl acylamidase.
• Oculocutaneous albinism and mental Disorder. A report of two autistic boys.
• Response of central monoaminergic neurons to lisuride: comparison with LSD.
• Hirschsprung''s disease: absence of serotonergic neurons in the aganglionic colon.
• Charybdotoxin, dendrotoxin and mast cell degranulating peptide block the voltage-activated K+ current of fibroblast cells stably transfected with NGK1 (Kv1.2) K+ chann...
• 1,10-Diaminodecane and 1,12-diaminododecane block NMDA receptor currents by an open channel mechanism.

Schools

---

• Yale Univ Sch Of Med

Conditions Treated

---

• Autonomic Disorders
• Convulsions
• Dystonia
• Background: yellow;'>Background: yellow;'>Background: yellow;'>Background: yellow;'>Background: yellow;'>Background: yellow;'>Epilepsy
• View All

Doctors Specialties

---

• Neurology
• Psychiatry

Accepted Insurances

---

Awards

---

• CMS Meaningful Use Stage 1 Certification

Education

---

• Johns Hopkins University
• National Institutes of Health Clinical Center
• Yale University School of Medicine

Hospital

---

• University of California, Davis Medical Center

Drug Facts

---

NPI NUMBER		1538357033
NPPES Provider LastName		ROGAWSKI
NPPES Provider FirstName		MICHAEL
NPPES Provider ZIPCode		958172307
NPPES Provider State		CA
Specialty Description		Neurology
Total Claim Count		189.0
Distinct Opioid Count		0.0
Opioid Claim Count		0.0
Percent Opioid Claims		0.0

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1538357033
Last Name Of The Provider	ROGAWSKI
First Name Of The Provider	MICHAEL
View All

Similar Doctors

---

	Dr. Jack E. Rozance, MD This Doctor is OpenDoctor Recommended.
	Dr. Nidal A. Khalili, MD This Doctor is OpenDoctor Recommended.
	Dr. Stephen K. Wong, MD This Doctor is OpenDoctor Recommended.
	Dr. William J. Au, MD This Doctor is OpenDoctor Recommended.
	Dr. Michael G. Adelberg, MD
	Dr. Vasanthi Krishna, MD This Doctor is OpenDoctor Recommended.
	Dr. Michelle L. Apperson, MD This Doctor is OpenDoctor Recommended.
	Dr. A R. Ehyai Jr., MD This Doctor is OpenDoctor Recommended.
	Dr. Barbara J. Gardner, MD This Doctor is OpenDoctor Recommended.
	Dr. William H. Green Jr., MD
	Dr. Neal Mehra, MD This Doctor is OpenDoctor Recommended.
	Dr. Nazhiyath Vijayan, MD This Doctor is OpenDoctor Recommended.
	Dr. Ananth Shanmugam, MD This Doctor is OpenDoctor Recommended.
	Dr. Elizabeth N. Gutierrez, MD This Doctor is OpenDoctor Recommended.
	Dr. Derek L. Holder, MD This Doctor is OpenDoctor Recommended.
	Dr. Glen C. Jickling, MD
	Dr. Amar P. Patel, MD
	Dr. Alice Park, MD
	Dr. Bryant N. Sheehy, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog